Gail Dutton

Gail Dutton

Gail Dutton has covered the biotech industry since soon after its inception, focusing on the intersection of business and science.

ARTICLES BY GAIL DUTTON

  • Whistleblower Best Practices
    Whistleblower Best Practices

    At some point in the life of a pharmaceutical company, a whistleblower is likely to come forward with allegations of wrongdoing. The intricacies of marketing alone can create a minefield of potential mistakes. Your best defense begins now.

  • How The FDA Views Natural Language Processing
    How The FDA Views Natural Language Processing

    According to speakers at an FDA workshop, natural language processing (NLP) can be a useful way to extract meaningful information from unstructured data, such as text and tables from electronic health records (EHRs), journals, and social media, but it isn’t ready for full-scale use.

  • Automation Cuts Drug Development To 5 Years
    Automation Cuts Drug Development To 5 Years

    Automation’s advances and widespread integration into the scientific workflow can reduce drug R&D time from the usual 15 years to five, according to a study released by Frost & Sullivan. “Robotics already is meeting most relevant needs in drug discovery. Its impact in the coming few years will be remarkable,” says Cecilia Van Cauwenberghe, associate fellow and industry analyst, TechVision at Frost & Sullivan. “Robotics will make pharmaceutical processes significantly more costand time-effective and allow precise, real-time documentation of every task. That, in turn, contributes to process optimization.”

  • Precompetitive Partnerships Skyrocket
    Precompetitive Partnerships Skyrocket

    The number of precompetitive collaborations among pharmaceutical companies increased nine-fold between 2005 and 2014 when compared against the 1995 to 2005 period. Meanwhile, traditional partnerships merely doubled, according to “Partnering for Progress: How Collaborations are Fueling Biomedical Advances,” a new study by Deloitte and PhRMA.

  • Pharma Embraces The Cloud ... Cautiously
    Pharma Embraces The Cloud ... Cautiously

    Pharmaceutical companies that have, until recently, eschewed cloud computing are migrating applications into that environment. Adoption began gradually, first with functions that aren’t mission-critical. After a few years’ experience, they’re still cautious, seeking to adopt the cloud strategically while minimizing risks.

  • Pharma Field Trips: Is Hosting The FDA A Good Idea?
    Pharma Field Trips: Is Hosting The FDA A Good Idea?

    Inviting FDA scientists into your manufacturing facility or laboratory for one or two days may feel unsettling, but it can be rewarding when the visits are designed to bring FDA scientists up to speed on real-world issues and new technologies.

  • Most U.S. Pharmas Ignore Cuba, Despite Relaxed Rules
    Most U.S. Pharmas Ignore Cuba, Despite Relaxed Rules

    Two American organizations go on the record to discuss their work with Cuban researchers and their efforts to bring innovative research involving cancer vaccines and levels of consciousness (e.g., comas, brain death) to American patients.

  • Cell Therapy Regulations Approach Their Inflection Point
    Cell Therapy Regulations Approach Their Inflection Point

    The need for discussions regarding guidelines for the development of therapeutics made from human cells, tissues, and cell- and tissue-based products has been building for a long time.

  • Biotech Bounces Back: A Tale Of Two Companies
    Biotech Bounces Back: A Tale Of Two Companies

    The fascinating stories of how Akari Therapeutics and Oncolytics Biotech each faced devastating challenges in their evolution and ultimately reinvented themselves.

  • The Common Elements Of Top-Performing Pharmas
    The Common Elements Of Top-Performing Pharmas

    Top-performing pharmaceutical companies aren’t like their peers. The top six companies have each found their own “secret sauce” that, according to a recent Accenture report, helps them dominate their markets and boost profit margins far beyond those of their peers.

More From Gail Dutton